Profiel
Chang Rung Chen was the founder of Processa Pharmaceuticals, Inc. (founded in 2011) where he held the title of Senior Director-Translational Science until 2022.
He also held the position of Director-Bimolecular Discovery at ArQule, Inc. and Director-Translational Research & Pharmacology at Questcor Pharmaceuticals, Inc. from 2015 to 2016.
Dr. Chen received his graduate and doctorate degrees from New York University and his undergraduate degree from Tunghai University.
Eerdere bekende functies van Chang Rung Chen
| Bedrijven | Functie | Einde |
|---|---|---|
| PROCESSA PHARMACEUTICALS, INC. | Founder | 01-11-2022 |
| QUESTCOR PHARMACEUTICALS INC | Corporate Officer/Principal | 01-01-2016 |
| ARQULE, INC. | Corporate Officer/Principal | - |
Opleiding van Chang Rung Chen
| New York University | Doctorate Degree |
| Tunghai University | Undergraduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| PROCESSA PHARMACEUTICALS, INC. | Health Technology |
| Bedrijven in privébezit | 2 |
|---|---|
ArQule, Inc.
 ArQule, Inc. Pharmaceuticals: MajorHealth Technology ArQule, Inc. is a biopharmaceutical company, which engages in the research and development of therapeutics to treat cancers and rare diseases. The company was founded in 1993 and is headquartered in Burlington, MA. | Health Technology |
Questcor Pharmaceuticals, Inc.
 Questcor Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Questcor Pharmaceuticals, Inc. was engaged in development, marketing and sale of prescription drugs. It operated as a biopharmaceutical company which focuses on the treatment of patients with serious, difficult-to-treat autoimmune and inflammatory disorders. The company's primary product was H.P. Acthar Gel, an injectable drug for the treatment of proteinuria in the nephrotic syndrome of the idiopathic type, or NS, the treatment of acute exacerbations of multiple sclerosis, or MS, in adults, the treatment of infantile spasms, or IS, in infants and children under two years of age, and the treatment of certain rheumatology related conditions, including the treatment of the rare and closely related neuromuscular disorders dermatomyositis and polymyositis. Questcor Pharmaceuticals was founded in September 1992 and was headquartered in Anaheim, CA. | Health Technology |
